Efficacy and safety of remimazolam in bronchoscopic sedation: A meta-analysis

Table 5 Pooled results of subgroup analyses of adverse event rates for remimazolam vs propofol, midazolam, and dexmedetomidine

Control	Complications	Relative risk	95%CI	I2 value (%)	P value for effect
Propofol	Hypotension	0.45	(0.32, 0.64)	0.0	0.000
	Hypertension	2.00	(0.82, 4.85)	37.6	0.125
	Respiratory depression	0.48	(0.30, 0.76)	78.4	0.002
	Hypoxemia	0.36	(0.15, 0.87)	-	0.023
	Bradycardia	0.33	(0.08, 1.33)	0.0	0.119
	Tachycardia	0.67	(0.27, 1.64)	-	0.378
	Injection pain	0.04	(0.01, 0.28)	-	0.001
Midazolam	Hypotension	0.85	(0.65, 1.12)	-	0.247
	Hypertension	1.03	(0.83, 1.28)	-	0.766
	Respiratory depression	0.53	(0.14, 2.00)	-	0.350
	Hypoxemia	1.16	(0.68, 1.97)	-	0.595
	Bradycardia	0.99	(0.29, 3.37)	-	0.983
	Tachycardia	2.07	(0.11, 38.05)	-	0.624
	Injection pain	1.15	(0.06, 23.72)	-	0.927
Dexmedetomidine	Hypotension	0.61	(0.40, 0.95)	-	0.797
	Hypertension	0.67	(0.11, 3.87)	-	0.652
	Respiratory depression	1.00	(0.14, 6.91)	-	1.000
	Hypoxemia	0.80	(0.33, 1.91)	-	0.616
	Bradycardia	1.50	(0.26, 8.71)	-	0.652